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Abstract
The purpose of this study was to examine the association between perceived family
support, either positive or negative, and adherence to antiretroviral medication
regimens among HIV-positive individuals in the Kathmandu Valley, Nepal. We mea-
sured past 3-month antiretroviral adherence among 233 HIV-positive individuals, in
relation to perceived family support, both positive (in terms of emotional and instru-
mental support) and negative (in the form of negative interactions), using the 10-item
Nepali Family Support and Difficulty Scale. Medium and high levels of perceived
emotional support from family were associated with reduced risk of antiretroviral
nonadherence, compared with low levels of perceived emotional support (adjusted
odds ratio [AOR] ¼ 0.37, 95% confidence interval [CI] [0.16, 0.88], and AOR ¼ 0.23,
95% CI [0.08, 0.64], respectively). Conversely, higher levels of felt emotional distance
(AOR ¼ 1.46, 95% CI [1.00, 2.14]) and experienced physical harm (AOR ¼ 2.04, 95%
CI [1.07, 3.91]) were associated with increased risk of nonadherence. The results
support the recommendation that service providers need to be aware of the signifi-
cant role of family support in shaping antiretroviral adherence and to consider ways
to strengthen positive family support while minimizing negative family interactions to
increase adherence rates.
Keywords
family, social support, antiretroviral therapy, medication adherence, HIV or
AIDS, Nepal
Background
Promoting and sustaining long-term medication adherence among HIV-positive
individuals has become an important element of modern HIV care. Globally, the
availability of antiretroviral therapy (ART) is associated with reduced rates of
morbidity and mortality as well as improved quality of life for HIV-positive
individuals.1–4 To realize the full benefits of ART, however, it is important for
HIV-positive individuals to maintain high levels of medication adherence.5–8
Dramatic increases in viral load have been found within days of treatment
withdrawal or missed antiretroviral doses.9 Moreover, irregular adherence to
medication can lead to treatment failure as well as to the development of
drug-resistant strains of HIV.10
Family support has a potentially important role to play in promoting ART
adherence among HIV-positive individuals. Studies have found a positive asso-
ciation between measures of family support and ART adherence.11–14 Such
results indicate that familial ties play an important role in health behaviors,
through illness adaptation,15 coping,16 and medical or health care utilization.17
Similarly, a supportive family environment has been found to decrease disease-
related negative affect18,19 among HIV-positive individuals, particularly for
those harboring fears about the prospect of isolation and rejection by family
members.20–22
Conversely, other studies have found nonsignificant23 or negative effects of
family interactions on ART adherence among HIV-positive individuals when
there is a fear of stigma and discrimination.24–26 In families with low levels of
attachment, affected individuals may not discuss personal issues,27 including
HIV diagnosis, ART initiation, or use of antiretroviral medicines. Often,
HIV-positive individuals may not disclose their health status to family
members,28 leading to a lack of family support to improve medication adherence
2
and other health outcomes. These findings underscore the importance of inves-
tigating the influence of both positive and negative aspects of family support on
ART adherence. Yet, few studies have examined the potential impacts of posi-
tive and negative interactions within familial relationships simultaneously.
To fill this gap, we explored the association between both perceived positive
and perceived negative family support and ART nonadherence among HIV-
positive individuals in the Kathmandu Valley, Nepal. The findings of this
study will be useful in developing more carefully tailored interventions to pro-
mote ART adherence and, thereby, to maintain favorable treatment outcomes
over the long term.
Methods
Design and Participants
This study is based on data from the Positive Living with HIV study, a longi-
tudinal study conducted among HIV-positive individuals in the Kathmandu
Valley, Nepal, details of which have been reported elsewhere.29–33 The
Kathmandu Valley consists of three districts (Kathmandu, Bhaktapur, and
Lalitpur) with an estimated population of 2.5 million in 2011.34 Nepal shares
several common characteristics with other resource-limited countries in Asia,
including a high burden of HIV among the high-risk populations but low preva-
lence in the general population, and low ART coverage.35 Although overall HIV
prevalence was 0.3% in 2011, with an estimated 50,200 adults (aged 15–49 years)
living with HIV,36 reported HIV prevalence was much higher among certain
high-risk populations, including injection drug users (6.3%) and female sex
workers (4.2%).37 Regarding treatment coverage, free ART services were intro-
duced in the country in 2004, but coverage of eligible individuals was only 23.7%
in 2011.37 Seven of the 44 total ART sites in the country are located in the
Kathmandu Valley.38 Several nongovernmental organizations (NGOs) have
been assisting these sites by facilitating the hospital visits of HIV-positive indi-
viduals for consultation, ART initiation, CD4+ cell count monitoring, and
other services.32 As necessary, these NGOs also collect antiretroviral medicines
for their registered members from the designated ART clinic and distribute them
to their homes.
In February–March 2010, we recruited 322 participants through a network
of five NGOs working with HIV-positive individuals in the Kathmandu
Valley. The inclusion criteria for participants were as follows: aged 18 to 60
years, self-reported diagnosis of HIV-positive status, residence in the
Kathmandu Valley, and willingness to participate in the study voluntarily.
For this study, participants who were not under ART were excluded, resulting
in a final study population of 233 HIV-positive individuals (122 men and 111
women).
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Procedures
Data were collected by face-to-face interview using a structured questionnaire
administered in Nepali. Adopting items from previous studies conducted in
Nepal,39–42 the questionnaire was first developed in English. Additional ques-
tions were then translated into the Nepali language and back-translated into
English for verification of semantic equivalence. The Nepali version was revised
based on back-translation, pretested among 30 participants, and finalized on the
basis of the pretest results.
Four interviewers were hired for data collection. The first author provided a
day-long training on the contents of the questionnaire and interview techniques.
Using the Nepali language questionnaire, the interviewers conducted in-person
interviews individually in a private setting. Each interview lasted approximately
45 to 60 minutes. Each participant received 100 Nepali rupees (approximately
US $1.35) to cover transportation costs. The first and last authors supervised the
fieldwork. They organized review sessions at the end of each day with all the
field-team members. In these sessions, they reemphasized the importance of
reassuring participants of the confidentiality of their information, checking the
completeness of the survey prior to interview completion, and asking questions
to each participant in the same manner to minimize within – and between-
participant variability.
Measures
Perceived family support. As reported earlier,43,44 perceived family support was
measured using the 10-item Nepali Family Support and Difficulty Scale
(a ¼ .87) specifically developed for use in Nepal.45 The items measured partici-
pants’ perceptions of both support from and negative interactions with family
members in the past year. Response categories ranged from 0 Not at all to 3 All
the time. Before analysis, we reversed the scores for negatively formulated items
measuring negative family interaction. Then, we obtained the total perceived
family support scores by summing all 10 items. With a range of 0 to 30,
higher scores indicated higher levels of perceived family support. Finally, the
total score was categorized by tertiles into high (27–30), medium (23–26), and low
(0–22) levels for statistical analyses.
To measure specific dimensions of family support, the scale was further
divided into three subscales: emotional support (four items, a ¼ .79, e.g.,
“How much can you share your feelings with your family members?”), instru-
mental support (two items, a ¼ .66, e.g., “How much does your family meet
your basic needs?”), and negative interaction (four items, a ¼ .74, e.g., “How
much do you feel your family has physically hurt you?”). Similar to overall
scores, total scores on each subscale were categorized as high, medium, and
low by tertiles.
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ART adherence. ART adherence was measured by asking participants to recall
their intake of prescribed doses of antiretroviral medicines in the previous 3
months. To minimize recall bias, first, participants were asked how many doses
of antiretroviral medicines they had missed over the previous 4 days. Then, they
were asked if they forgot to take antiretroviral medicines over the previous 1
month, 2 months, and 3 months. As complete adherence is considered essential
in stopping HIV replication,5 participants who reported never forgetting to take 
their antiretroviral medicines in the past 3 months were considered as adherent,
while those who reported forgetting at least one dose during that same period
were categorized as nonadherent for the purposes of our study.
Covariates. Adopting questionnaire items from those used in previous stu-
dies,39–42 we measured key sociodemographic, drug and alcohol use, and HIV-
specific clinical and psychological factors that might have potential associations
with ART adherence. We categorized participants’ education into Up to primary
or Secondary or higher levels from the reported years of formal education.
Similarly, we categorized participants’ employment status as Employed or
Unemployed from participants’ reports of their specific types of work. We
asked participants if they had disclosed their HIV status to any family members
(Yes or No). Participants’ current smoking status (Smoker or Nonsmoker) was
classified based on reported smoking frequency.46 We asked participants if they
had used any illicit drugs in the past 6 months (Yes or No) and if they had
consumed alcohol in the past 30 days (Yes or No). We assessed illness history by
asking, “In the past 12 months, did you suffer from any type of disease including
minor illnesses?” (Yes or No).
As reported elsewhere,47 we measured HIV symptom burden using a 16-item
HIV Symptom Index based on a 1-month recall period (a ¼ .92). The original
scale had 20 items.48 However, we omitted four items (Sadness, Anxiety, Sleep
trouble, and Sex problems) to avoid overlap with items in the measure of depres-
sive symptoms. The items had a 5-point response scale ranging from 0 I don’t
have this problem to 4 I have this problem and It bothers me a lot. We obtained the
total score for the scale by summing the scores of all 16 items. We then categor-
ized the score level as high (above the median) or low (below or equal to the
median) for statistical analysis.
We measured internalized stigma using a seven-item scale (a ¼ .74) adopted
from a previous study carried out among HIV-positive individuals49 (e.g., “I am
ashamed that I am HIV-positive”). Participants indicated either agreement (1) or
disagreement (0) with each of the scale items. We obtained the total score for
internalized stigma by summing the scores of all seven items, with higher scores
suggesting a greater burden of felt stigma. Finally, the score was categorized as
high (equal to or above the median) or low (below the median) for statistical
analysis.
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We used the 21-item Beck Depression Inventory-I, Nepali version50,51 to 
assess depressive symptoms over the past 2 weeks (a ¼ .89). Participants 
responded to the items on a 4-point Likert scale, with a total range for the instru-
ment of 0 to 61. The Nepali version of the scale has been validated for use in
Nepal.50 Results from the validation study indicate that a score of 20 or higher 
indicates moderate to severe depression requiring mental health intervention.
Statistical Analyses
First, we report proportions for sociodemographic, health, alcohol, drug, and
ART adherence-related variables, as well as mean and standard deviation
(SD), or median and interquartile range (IQR) as appropriate. Second, we
compared participant characteristics according to reported high, medium, or
low levels of perceived family support. Third, we tested the association
between perceived family support and ART nonadherence using bivariate
and multivariable logistic regression analyses to estimate AORs with 95%
CIs. For this, we first examined the bivariate associations between each cov-
ariate and ART nonadherence. As Katz52 recommends, we then performed
multivariable logistic regression analysis including all covariates that had a
bivariate p value .10. Our final multivariable model adjusted for ART dur-
ation, illicit drug use, depressive symptoms, and perceived family support.
Fourth, we examined associations of the emotional support, instrumental sup-
port, and negative interaction subscale scores with ART nonadherence using
multivariable logistic regression analyses adjusting for ART duration, illicit
drug use, and depressive symptoms. Finally, we examined the association of
each individual perceived family support item with ART nonadherence using
multivariable logistic regression analyses. We used SPSS Statistics 22.0 (SPSS
Inc., Chicago, USA) to perform all of the analyses, with statistical significance
set at p < .05.
Ethical Considerations
All participants were individually informed of the study procedures using a
prepared information sheet, after which they voluntarily provided written
informed consent to participate in the study. All interviews were conducted
in a private setting. Prior to each interview, interviewers reassured participants
of the confidentiality of their personal information, protections reinforced
by using numerical codes in place of names in all records. The study proced-
ures were approved by the Research Ethics Committee of the Nepal
Health Research Council in Kathmandu, Nepal; the National Center for
Global Health and Medicine in Tokyo, Japan; Waseda University in Tokyo,
Japan; and the institutional review board of the University of Massachusetts
Amherst.
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Results
General Characteristics
The mean age of the participants was 35.2 (SD ¼ 7.1) years. The median dur-
ation since testing positive for HIV was 53 (IQR ¼ 24–95) months. Overall,
52.4% of participants were men, 71.2% were currently married, 69.1% were
employed, and 21.2% reported illicit drug use in the past 6 months (Table 1).
With respect to the ART regimen, 226 (96.3%) of participants were on two
Nucleoside Reverse Transcriptase Inhibitors (NRTI; either Lamivudine and
Zidovudine or Lamivudine and Stavudine) and one Nonnucleoside Reverse
Transcriptase Inhibitor (either Efavirenz or Nevirapine); six (2.6%) participants
were on two NRTI (Tenofovir and Didanosine) and one Protease Inhibitor
(Lopinavir or Ritonavir); and one (0.4%) participant was on three NRTI
(Abacavir, Zidovudine, and Lamivudine). The median duration on antiretro-
viral treatment was 24 months (IQR ¼ 9–39). Nearly two thirds of participants
reported a history of disease in the past 12 months. The mean score (SD) for
internalized stigma was 10.9 (2.2).
Characteristics of Participants by Perceived Family Support
The mean score for perceived family support was 22.5 (SD ¼ 6.2). Higher pro-
portions of women and currently single participants reported low levels of per-
ceived family support (Table 2). In addition, higher proportions of participants
with lower levels of education, with a history of any disease in the past 12
months, and with higher levels of internalized stigma reported low levels of
perceived family support.
Rates of ART Nonadherence
None of the participants reported missing any doses of antiretroviral medicines in
the past 4 days. Seven participants (3.0%) reported missing at least one dose of
antiretroviral medicines during the past week. Nine participants (3.9%) reported
missing doses of antiretroviral medicines in the past month, 18 participants
(7.7%) in the past 2 months, and 41 participants (17.6%) in the past 3 months.
Association Between Perceived Family Support and ART
Nonadherence
A higher proportion of participants with low levels of perceived family support
reported a history of missing antiretroviral medication doses in the past
3 months; the nonadherence rate among those with low levels of perceived
family support was 25.6%, whereas the rates among those with medium and
high levels of perceived family support were 15.9% and 9.2%, respectively
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Table 1. Demographic and Health Characteristics of Participants (N ¼ 233).
Characteristic n (%)
Age (years)
20–34 119 (51.1)
35–60 114 (48.9)
Sex
Female 111 (47.6)
Male 122 (52.4)
Current marital status
Single 67 (28.8)
Married 166 (71.2)
Educationa
Up to primary 105 (45.5)
Secondary or higher 126 (54.5)
Employed
No 72 (30.9)
Yes 161 (69.1)
Months since testing HIV positive
1–52 116 (49.8)
53+ 117 (50.2)
HIV disclosure to any family memberb
No 40 (17.4)
Yes 190 (82.6)
Illicit drug use, past 6 months
No 207 (88.8)
Yes 26 (21.2)
Current smoker
No 137 (58.8)
Yes 96 (41.2)
Alcohol use, past 30 days
No 212 (91.0)
Yes 21 (9.0)
Current antiretroviral therapy regimen
Lamivudine, Zidovudine, and Nevirapine 117 (50.2)
Lamivudine, Zidovudine, and Efavirenz 61 (26.2)
Lamivudine, Stavudine, and Nevirapine 44 (18.9)
Lamivudine, Stavudine, and Efavirenz 4 (1.7)
Tenofovir, Didanosine, and Lopinavir or Ritonavir 6 (2.6)
Abacavir, Zidovudine, and Lamivudine 1 (0.4)
(continued)
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(Table 3). In bivariate logistic regression analysis, low levels of perceived family
support were associated with increased risk of ART nonadherence compared
with high levels of perceived family support (OR ¼ 3.38, 95% CI [1.28, 8.91]). In
multivariable logistic regression analysis, those with low levels of perceived
family support had 3.39-fold higher odds of reporting ART nonadherence com-
pared with those with high levels of perceived family support. Similarly, those
participants who had been on antiretroviral treatment for longer durations and
who reported illicit drug use were more likely to report a history of ART
nonadherence.
Table 4 shows the results of multivariable analyses for perceived family sup-
port subscale scores and individual items associated with ART nonadherence. Of
the three subscales, only emotional support was statistically associated with ART
nonadherence; namely, reporting medium (AOR ¼ 0.37, 95% CI [0.16, 0.88]) and
high (AOR ¼ 0.23, 95% CI [0.08, 0.64]) levels of emotional support were asso-
ciated with reduced risk of ART nonadherence compared with reporting low
levels of emotional support. All four items of emotional support were significantly
associated with ART adherence after adjusting for potential confounders.
Conversely, two negative interaction items were statistically associated with
ART nonadherence. Higher levels of felt emotional distance from family was
associated with increased risk of ART nonadherence (AOR ¼ 1.46, 95%
CI [1.00, 2.14]). Similarly, a history of higher levels of physical harm by family
members was associated with increased risk of ART nonadherence (AOR ¼ 2.04,
95% CI [1.07, 3.91]). In addition, a higher proportion (n ¼ 6, 40.0%) of partici-
pants who reported the experience of more frequent physical harm from family
had not disclosed their HIV status to their families than among those who
reported less frequent physical harm from family (n ¼ 34, 15.8%, p ¼ .017).
Discussion
This study revealed that the experience of a low level of perceived family sup-
port—emotional support, in particular—was associated with increased risk of
Table 1. Continued.
Characteristic n (%)
Months on antiretroviral therapy
1–23 114 (48.9)
24+ 119 (51.1)
History of any disease in past 12 months
No 83 (35.6)
Yes 150 (64.4)
aTwo participants did not respond to this question.
bThree participants did not respond to this question.
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Table 2. Sociodemographic and Health Characteristic of Participants According to
Reported Level of Perceived Family Support (N ¼ 233).
Variable
Perceived family support levela
p
High (n¼ 65) Medium (n¼ 82) Low (n¼ 86)
n (%) n (%) n (%)
Age (years)
20–34 29 (24.4) 43 (36.1) 47 (39.5) .452
35–60 36 (31.6) 39 (34.2) 39 (34.2)
Sex
Female 16 (14.4) 35 (31.5) 60 (54.1) <.001
Male 49 (40.2) 47 (38.5) 26 (21.3)
Current marital status
Single 13 (19.4) 18 (26.9) 36 (53.7) .003
Married 52 (31.3) 64 (38.6) 50 (30.1)
Educationb
Up to primary 17 (16.2) 38 (36.2) 50 (47.6) <.001
Secondary or higher 47 (37.3) 44 (34.9) 35 (27.8)
Employed
No 17 (23.6) 26 (36.1) 29 (40.3) .597
Yes 48 (29.8) 56 (34.8) 57 (35.4)
Months since testing HIV positive
1–52 32 (27.6) 43 (37.1) 41 (35.3) .822
53+ 33 (28.2) 39 (33.3) 45 (38.5)
HIV disclosure to any family memberc
No 6 (15.0) 13 (32.5) 21 (52.5) .041
Yes 58 (30.5) 69 (36.3) 63 (33.2)
Illicit drug use, past 6 months
No 55 (26.6) 74 (35.7) 78 (37.7) .442
Yes 10 (38.5) 8 (30.8) 8 (30.8)
Current smoker
No 33 (24.1) 47 (34.3) 57 (41.6) .150
Yes 32 (33.3) 35 (36.5) 29 (30.2)
Alcohol use, past 30 days
No 57 (26.9) 77 (36.3) 78 (36.8) .423
Yes 8 (38.1) 5 (23.8) 8 (38.1)
(continued)
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ART nonadherence among the surveyed HIV-positive individuals. Moreover,
more frequent experience of physical harm by family and higher levels of felt
emotional distance from family members was associated with increased risk of
ART nonadherence. To our knowledge, this is the first study exploring the
association of both positive and negative aspects of family support with ART
adherence among HIV-positive individuals, while adjusting for potential
confounders.
Adding to existing literature on the positive association between overall
family support and ART adherence,11–14 our study provides further information
on the distinct roles of both positive and negative elements of family support on
ART adherence among HIV-positive individuals. In our study, positive forms of
family support, particularly in the emotional domain, appear to be protective
toward improving ART adherence. As reported by previous studies,18,19 percep-
tion of a supportive family environment in the form of felt emotional support is
likely to decrease negative affect associated with the disease, probably by
increasing self-esteem and adaptive coping. High levels of family attachment
and adaptiveness are expected in a positive family environment, as reflected in
the items of the emotional support subscale. Family members residing in such an
environment are likely to adapt better to unexpected events and transitions27
such as HIV diagnosis, treatment initiation, and adverse side effects or setbacks
in the disease progression. Furthermore, HIV or AIDS-related knowledge and
treatment may be expected to be better absorbed53 and used to maintain medi-
cation adherence in such environments.
Table 2. Continued.
Variable
Perceived family support levela
p
High (n¼ 65) Medium (n¼ 82) Low (n¼ 86)
n (%) n (%) n (%)
History of any disease, past 12 months
No 28 (33.7) 34 (41.0) 21 (25.3) .023
Yes 37 (24.7) 48 (32.0) 65 (43.3)
Months on antiretroviral therapy
1–23 30 (26.3) 38 (33.3) 46 (40.4) .567
24+ 35 (29.4) 44 (37.0) 40 (33.6)
Internalized stigma score (Median: 11)
Low (7–10) 42 (41.6) 34 (33.7) 25 (24.8) <.001
High (11–14) 23 (17.4) 48 (36.4) 61 (46.2)
aPerceived family support scores (High: 27–30, Medium: 23–26, and Low: 0–22).
bTwo participants did not respond to this question.
cThree participants did not respond to this question.
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Table 3. Odds Ratios and 95% CIs for ART Nonadherence by Level of Perceived Family
Support (N¼ 233).
Variable
ART nonadherence
OR (95% CI) AOR (95% CI) P
Yes No
n (%) n (%)
Perceived family support
High (27–30) 6 (9.2) 59 (90.8)
Medium (23–26) 13 (15.9) 69 (84.1) 1.85 (0.66–5.17) 1.86 (0.63–5.46) 0.259
Low (0–22) 22 (25.6) 64 (74.4) 3.38 (1.28–8.91) 3.39 (1.19–9.65) 0.022
Age (in years)
20–34 25 (21.0) 94 (79.0)
35–60 16 (14.0) 98 (86.0) 0.61 (0.30–1.22)
Sex
Female 22 (19.8) 89 (80.2)
Male 19 (15.6) 103 (84.4) 0.74 (0.38–1.96)
Current marital status
Single 13 (19.4) 54 (80.6)
Married 28 (16.9) 138 (83.1) 0.84 (0.40–1.74)
Educationa
Up to primary 19 (18.1) 86 (81.9)
Secondary or higher 22 (17.5) 104 (82.5) 0.95 (0.48–1.88)
Employed
No 11 (15.3) 61 (84.7)
Yes 30 (18.6) 131 (81.4) 1.27 (0.59–2.70)
Months since testing HIV positive
1–52 16 (13.8) 100 (86.2)
53+ 25 (21.4) 92 (78.6) 1.69 (0.85–3.38)
ART duration (in months)
1–23 14 (12.3) 100 (87.7)
24+ 27 (22.7) 92 (77.3) 2.09 (1.03–4.24) 3.01 (1.38–6.56) 0.005
HIV disclosure to any family member
No 7 (17.5) 33 (82.5)
Yes 34 (17.9) 156 (82.1) 0.97 (0.39–2.38)
Illicit drug use, past 6 months
No 33 (15.9) 174 (84.1)
Yes 8 (30.8) 18 (69.2) 2.34 (0.94–5.83) 3.17 (1.15–8.69) 0.025
Current smoker
No 21 (15.3) 116 (84.7)
Yes 20 (20.8) 76 (79.2) 1.45 (0.73–2.86)
Alcohol use, past 30 days
No 37 (17.5) 175 (82.5)
Yes 4 (19.0) 17 (81.0) 1.11 (0.35–3.49)
(continued)
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In terms of negative family interactions, higher levels of physical harm by family
and higher levels of felt emotional distance from family significantly increased the
likelihood of ART nonadherence among our participants. The familial relationships
can be a source of tension in families with low levels of attachment27 or having
frequent negative interactions. In such environments, family members may not be
helpful in supporting individuals to accept their HIV diagnosis, transition smoothly
to ART initiation, or maintain consistent ART adherence. One previous study
reported a negative effect of home-based peer adherence support on treatment
outcomes among HIV-positive individuals residing in the most vulnerable or dys-
functional families.54 Some HIV-positive individuals in such families may not dis-
close their HIV status to their family members. In our study, for example, a
significantly higher proportion of the participants who reported experiencing phys-
ical harm by their family members had not disclosed their HIV status to any of their
family members. However, a history of HIV nondisclosure was not statistically
associated with increased risk of ART nonadherence among our participants.
Similar to the results of previous studies carried out in China55 and India,56
we found that HIV-positive individuals on ART for longer periods were at
significantly increased risk of ART nonadherence compared with those on
ART for shorter periods. Unlike our study, however, a separate independent
study conducted in Kathmandu did not find any statistical association between
the length of ART and ART adherence.57 The differences in participant
Table 3. Continued.
Variable
ART nonadherence
OR (95% CI) AOR (95% CI) P
Yes No
n (%) n (%)
Depressive symptoms
No (BDI-I< 20) 23 (13.8) 144 (86.2)
Yes (BDI-I 20) 18 (17.3) 48 (72.7) 2.34 (1.16–4.71) 2.10 (0.97–4.54) 0.059
HIV symptom burden
Low (16–32) 16 (13.7) 101 (86.3)
High (33–64) 25 (21.6) 91 (78.4) 1.73 (0.87–3.45)
History of any disease, past 12 months
No 13 (15.7) 70 (84.3)
Yes 28 (18.7) 122 (81.3) 1.23 (0.60–2.54)
Internalized stigma score
Low (7–10) 16 (15.8) 85 (84.2)
High (11–14) 25 (18.9) 107 (81.1) 1.24 (0.62–2.47)
Note. AOR¼ adjusted odds ratio; CI¼ confidence interval; OR¼odds ratio; ART¼antiretroviral therapy;
BDI-I¼ Beck Depression Inventory-I.
aTwo participants did not respond to this question.
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recruitment strategy (community-based approach in our study vs. clinic-based
approach in the other) might explain the discrepancies in these findings.
Regardless, the implications of our findings are that HIV-positive individuals
would benefit from family support for better adherence over time.
In our study, the rate of nonadherence was higher among those HIV-positive
individuals reporting a history of any illicit drug use compared with those with-
out such a history. Consistent with our results, previous studies have also
Table 4. Multiple Logistic Regression Analyses on the Association Between Individual
Perceived Family Support Items and ART nonadherence (N¼ 233)a.
Itemb AOR (95% CI) P
Emotional support
Feeling shown love and caring by family 0.65 (0.45–0.95) 0.026
Feeling have an important role in family 0.61 (0.40–0.92) 0.019
Feeling involved in family decision making 0.69 (0.50–0.95) 0.024
Feeling able to share feelings with family 0.62 (0.44–0.88) 0.007
Total emotional support score
High (10–12)
Medium (7–9) 0.37 (0.16–0.88) 0.025
Low (0–6) 0.23 (0.08–0.64) 0.005
Instrumental support
Feeling basic needs (food/clothes) met in family 1.03 (0.60–1.77) 0.894
Feeling supported by family when sick 0.77 (0.55–1.07) 0.120
Total instrumental support score
High (6)
Medium (5) 0.62 (0.24–1.59) 0.326
Low (0–4) 0.50 (0.21–1.14) 0.102
Negative interaction
Feeling disliked by family 1.33 (0.90–1.96) 0.143
Feeling (emotionally) distant from family 1.46 (1.00–2.14) 0.048
Having been physically hurt by family member(s) 2.04 (1.07 –3.91) 0.030
Feeling exploited (for household and farming) by family 1.36 (0.92–2.00) 0.122
Total negative interaction score
High (12)
Medium (11) 1.71 (0.61–4.76) 0.299
Low (0–10) 1.38 (0.61–3.08) 0.432
Note. AOR¼ adjusted odds ratio; CI¼ confidence interval; ART¼antiretroviral therapy.
aSeparate analyses were done for each item of the perceived family support scale, adjusting for ART
duration, history of illicit drug use in the past six months, and depressive symptoms.
bEach individual item was assessed as a continuous variable.
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reported an association between illicit drug use and ART nonadherence among
HIV-positive individuals.57–60 This finding is not surprising, as current illicit
drug use is likely to be associated with disruptions in daily activities, thereby
leading to greater chance of failure to take antiretroviral medicines. This sug-
gests the need to provide particular support to HIV-positive individuals with a
history of illicit drug use to improve their medication adherence.
Limitations
Some limitations should be considered when interpreting our findings. First, we
used cross-sectional data for this study and thus cannot infer causality.
Longitudinal studies would be necessary to establish clear causal relationships.
Second, as our measurements of ART adherence and other variables are based
on self-report, participants’ responses might have been influenced by a social
desirability bias, despite our efforts to minimize such bias by assuring partici-
pants of the confidentiality of their information. Third, our study is based on
participants’ perceived rather than an objective measure of family support,
though the distinction may not actually be of real concern, as previous studies
have reported an even more important role for perceived support than network
size or received support in influencing health and adjustment criteria.61,62
Finally, caution is necessary in generalizing our study findings to the country’s
HIV-positive population as a whole, as our study participants do not represent a
random sample of HIV-positive individuals in the study area. More specifically,
our findings are applicable to individuals included in the networks of support
groups providing services to the HIV-positive population at the community level,
as commonly exist in resource-limited countries in Asia and other regions.
Conclusions
Positive family support in the form of perceived emotional support was asso-
ciated with higher levels of ART adherence, whereas negative family interactions
in the form of family-inflicted physical harm and higher levels of felt emotional
distance from family were associated with increased risk of ART nonadherence
among HIV-positive individuals in the Kathmandu Valley, Nepal.
Our findings have important implications for the design and testing of ART
adherence support interventions involving family members. Involving families of
HIV-positive individuals with high levels of perceived emotional support in
adherence support interventions might improve ART adherence. The goal of
the involvement of family members in such cases should be towards building on
strengths. On the other hand, involvement of the families of those with more
frequent experience of family-inflicted physical harm or higher levels of felt
emotional distance from family in adherence support interventions might be
more appropriate only with participants’ prior consent. The focus of the
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involvement of family members in such cases, however, should be geared toward
mitigating the harms. Our results may also be of interest to clinicians or other
health-care providers assisting HIV-positive individuals who are on ART.
Furthermore, our results would be useful in designing training programs for
outreach workers involved in providing home-based care services to HIV-posi-
tive individuals. However, further longitudinal studies on the role of family
support in improving ART adherence among HIV-positive individuals are
warranted.
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